March 28 2024
Avacta Group plc
("Avacta" or the "Group" or the "Company")
Investor Webinar
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce that Chief Executive Officer Dr. Alastair Smith will be hosting a webinar on Wednesday, 10 April 2024 at 5:30pm (BST).
The webinar will cover the Company's updated clinical data from the first-in-human Phase 1 trial of AVA6000, the first of the Company's pre|CISION™ peptide drug conjugates that targets chemotherapy to the tumor, which are to be presented at the 2024 American Association for Cancer Research Annual Meeting, taking place in San Diego, California from 5-10 April 2024. The updated clinical data will be presented in the Phase 1 Clinical Trials 2 Poster Session on 9 April 2024.
There will be a Q&A session for investors after the presentation and questions can be submitted pre-event as part of the registration process.
You can register for the event by using the following link:
https://www.turnerpope.com/register/
We are delighted to announce that the webinar will be chaired by news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com) and hosted by Turner Pope Investments.
-Ends-
For further information from Avacta Group plc, please contact:
| Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer Michael Vinegrad, Group Communications Director
| Tel: +44 (0) 1904 21 7070 |
|
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben Good
| Tel: +44 (0) 207 710 7600 |
| Peel Hunt (Joint Broker) James Steel / Chris Golden / Patrick Birkholm | Tel: +44 (0) 207 418 8900
|
| ICR Consilium (Media and IR) Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji | |
| | |
| Webinar enquiries Turner Pope Investments (TPI) Limited James Pope / Andrew Thacker | +44 (0) 20 3657 0050 www.turnerpope.com
|
About Avacta Group plc - https://www.avacta.com
Avacta Group is a UK-based company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.
Avacta has two divisions: an oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs, and a diagnostics division, focused on supporting healthcare professionals and broadening access to testing. Avacta's two proprietary platforms, Affimer® and pre|CISION™ underpin its cancer therapeutics whilst the diagnostics division leverages the Affimer® platform to drive competitive advantage in its markets.
The pre|CISION™ platform modifies chemotherapy to be activated only in the tumor tissue, reducing systemic exposure and toxicity. This is achieved by harnessing an enzyme called FAP which is highly upregulated in most solid tumors compared with healthy tissues, turning chemotherapy into a "precision medicine". The lead pre|CISION™ programme, AVA6000 a tumour activated form of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in safety compared with standard doxorubicin, and early signs of clinical activity.
To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
